IL322427A - טיפול בהפרעות נפשיות - Google Patents
טיפול בהפרעות נפשיותInfo
- Publication number
- IL322427A IL322427A IL322427A IL32242725A IL322427A IL 322427 A IL322427 A IL 322427A IL 322427 A IL322427 A IL 322427A IL 32242725 A IL32242725 A IL 32242725A IL 322427 A IL322427 A IL 322427A
- Authority
- IL
- Israel
- Prior art keywords
- dmt
- meo
- breastfeeding
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP23153996 | 2023-01-30 | ||
| EP23154014 | 2023-01-30 | ||
| PCT/EP2023/057885 WO2023186837A1 (en) | 2022-03-27 | 2023-03-27 | Treatment of postnatal depression |
| PCT/EP2023/057874 WO2023186827A1 (en) | 2022-03-27 | 2023-03-27 | 5-methoxy-n,n-dimethyltryptamine for the treatment of postpartum depression |
| PCT/EP2023/076819 WO2024160391A1 (en) | 2023-01-30 | 2023-09-27 | Treatment of mental disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL322427A true IL322427A (he) | 2025-09-01 |
Family
ID=96878788
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL322430A IL322430A (he) | 2023-01-30 | 2023-09-27 | 5-meo-dmt לשימוש בטיפול בדיכאון לאחר לידה |
| IL322427A IL322427A (he) | 2023-01-30 | 2023-09-27 | טיפול בהפרעות נפשיות |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL322430A IL322430A (he) | 2023-01-30 | 2023-09-27 | 5-meo-dmt לשימוש בטיפול בדיכאון לאחר לידה |
Country Status (8)
| Country | Link |
|---|---|
| EP (2) | EP4658267A1 (he) |
| JP (2) | JP2026505778A (he) |
| KR (2) | KR20250134717A (he) |
| CN (2) | CN120813347A (he) |
| AU (2) | AU2023427992A1 (he) |
| IL (2) | IL322430A (he) |
| MX (2) | MX2025008750A (he) |
| WO (2) | WO2024160392A1 (he) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4155306A1 (en) | 2021-01-15 | 2023-03-29 | Beckley Psytech Limited | Neuroactive ergoline analogue |
| US12534441B2 (en) | 2021-01-15 | 2026-01-27 | Beckley Psytech Limited | Tryptamine analogues |
| US11312684B1 (en) | 2021-02-10 | 2022-04-26 | Eleusis Therapeutics Us, Inc. | Pharmaceutically acceptable salts of psilocin and uses thereof |
| US12264131B2 (en) | 2022-08-19 | 2025-04-01 | Beckley Psytech Limited | Pharmaceutically acceptable salts and compositions thereof |
| US12246005B2 (en) | 2023-06-13 | 2025-03-11 | Beckley Psytech Limited | 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE069534T2 (hu) * | 2019-02-22 | 2025-03-28 | Gh Res Ireland Limited | 5-Metoxi-N,N-dimetiltriptamint (5-MeO-DMT) tartalmazó készítmény mentális rendellenességek kezelésében történõ alkalmazásra |
| FI4349407T3 (fi) | 2019-02-22 | 2025-06-02 | Gh Res Ireland Limited | 5-metoksi-n,n-dimetyylitryptamiini (5-meo-dmt) vaikean masennuksen hoitoon |
| US11406619B2 (en) * | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
-
2023
- 2023-09-27 AU AU2023427992A patent/AU2023427992A1/en active Pending
- 2023-09-27 JP JP2025544460A patent/JP2026505778A/ja active Pending
- 2023-09-27 IL IL322430A patent/IL322430A/he unknown
- 2023-09-27 CN CN202380095314.1A patent/CN120813347A/zh active Pending
- 2023-09-27 AU AU2023428136A patent/AU2023428136A1/en active Pending
- 2023-09-27 WO PCT/EP2023/076820 patent/WO2024160392A1/en not_active Ceased
- 2023-09-27 JP JP2025544463A patent/JP2026505780A/ja active Pending
- 2023-09-27 KR KR1020257028945A patent/KR20250134717A/ko active Pending
- 2023-09-27 CN CN202380094304.6A patent/CN120641095A/zh active Pending
- 2023-09-27 WO PCT/EP2023/076819 patent/WO2024160391A1/en not_active Ceased
- 2023-09-27 EP EP23782869.4A patent/EP4658267A1/en active Pending
- 2023-09-27 IL IL322427A patent/IL322427A/he unknown
- 2023-09-27 KR KR1020257028947A patent/KR20250138805A/ko active Pending
- 2023-09-27 EP EP23782216.8A patent/EP4658371A1/en active Pending
-
2025
- 2025-07-25 MX MX2025008750A patent/MX2025008750A/es unknown
- 2025-07-25 MX MX2025008749A patent/MX2025008749A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL322430A (he) | 2025-09-01 |
| KR20250134717A (ko) | 2025-09-11 |
| AU2023427992A1 (en) | 2025-09-18 |
| WO2024160391A1 (en) | 2024-08-08 |
| KR20250138805A (ko) | 2025-09-22 |
| JP2026505778A (ja) | 2026-02-18 |
| JP2026505780A (ja) | 2026-02-18 |
| AU2023428136A1 (en) | 2025-09-18 |
| CN120641095A (zh) | 2025-09-12 |
| EP4658267A1 (en) | 2025-12-10 |
| CN120813347A (zh) | 2025-10-17 |
| EP4658371A1 (en) | 2025-12-10 |
| WO2024160392A1 (en) | 2024-08-08 |
| MX2025008749A (es) | 2025-10-01 |
| MX2025008750A (es) | 2025-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240115550A1 (en) | Treatment of mental disorders | |
| US20240108602A1 (en) | Treatment of mental disorders | |
| IL322427A (he) | טיפול בהפרעות נפשיות | |
| IL322428A (he) | 5-מתוקסי-n,n-דימתילטריפטמין לשימוש בטיפול בהפרעות נפשיות אצל אמהות מניקות | |
| US20250241894A1 (en) | Treatment of mental disorders |